Released on July 17, 2003
New drugs to aid in the treatment of glaucoma and elevated blood lipid levels have been added to Saskatchewan's Drug Plan.In total, 19 drugs were approved for coverage as of July 1st, 2003 (see attached list). Some of the drugs are new additions while others are generic brands of existing medications.
One of the new drugs is rosuvastatin (Crestor). The medication is for the treatment of elevated lipid levels, which can take the form of high cholesterol and triglyceride levels. Another new drug receiving full coverage is latanoprost/timolol maleate, ophthalmic solution (Xalacom). It is a combination therapy used to treat glaucoma, a serious condition which can lead to a gradual loss of sight.
Four drugs were approved under Exception Drug Status (EDS) for use when specific criteria are met. Physicians and pharmacists can apply for coverage of EDS drugs on behalf of their patients.
One of the EDS drugs approved is anakinra (Kineret), a product that helps in the treatment of active rheumatoid arthritis.
"The benefits under our drug plan are targeted to people who need help the most and to those drugs that work the best," Health Minister John Nilson said. "The top priority of our Action Plan for Saskatchewan Health Care is improving the quality of health care services and access to care, while ensuring our health care system is sustainable in the future."
In 2002-03, there were 8.3 million prescriptions filled under the Drug Plan, with over $132 million in benefits being paid out. The Drug Plan is targeted to people with high drug costs, low incomes, or a combination of both.
Currently, the drug plan covers about 3,500 products and subsidizes the cost of prescription drugs for approximately 105,000 families.
People can contact the Drug Plan toll free at 1-800-667-7581, or in Regina at 787-3317.
-30-
For More Information, Contact:
| Mark Rathwell Health Regina Phone: (306)787-4083 |